Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.88 |
| ▸ | CA1 | P00915 | 4/20 | 0.88 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20936513 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL10697539 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL20915578 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL20915508 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL21389651 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL20936460 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL20915253 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL20915289 | 0.98 | CA2 (0.85) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL8054453 | 0.94 | CA2 (1.00) | CA2CA1HDAC8HDAC6HDAC7 | |
| SCHEMBL24932772 | 0.89 | CA2 (0.70) | CA2CA1HDAC8HDAC6HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947318-B2 | IgE anti-HMW-MAA antibody | IGEM THERAPEUTICS LIMITED (GB) | 2021-03-16 | — | — | US | disclosed |
| CN-106232598-B | Cycloalkyl-linked diheterocyclic derivatives | 辉瑞公司 | 2020-03-13 | — | — | CN | disclosed |
| US-20180094074-A1 | IGE ANTI-HMW-MAA Antibody | IGEM THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | US | disclosed |
| EP-2139869-A2 | AXL KINASE INHIBITORS USEFUL FOR THE TREATMENT OF CANCER OR HYPERPROLIFERATIVE DISORDERS | SuperGen, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008128072-A2 | AXL KINASE INHIBITORS USEFUL FOR THE TREATMENT OF CANCER OR HYPERPROLIFERATIVE DISORDERS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1924604-A1 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1828144-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007022172-A1 | HUMAN MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND IGF-II | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006053342-A2 | INTEGRIN ANTAGONISTS USEFUL AS ANTICANCER AGENTS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1233948-A4 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARM INC (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1233948-A1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001034574-A1 | STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |